145 related articles for article (PubMed ID: 27681117)
1. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.
Saultz JN; Kaffenberger BH; Taylor M; Heerema NA; Klisovic R
JAMA Dermatol; 2016 Dec; 152(12):1391-1393. PubMed ID: 27681117
[No Abstract] [Full Text] [Related]
2. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?
Helbig G
Eur J Intern Med; 2016 Jul; 32():e19-20. PubMed ID: 26968968
[No Abstract] [Full Text] [Related]
4. A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
Zhang Y; Qu S; Wang Q; Li J; Xu Z; Qin T; Huang G; Xiao Z
Leuk Lymphoma; 2018 Oct; 59(10):2506-2508. PubMed ID: 29384404
[No Abstract] [Full Text] [Related]
5. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
8. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
9. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
10. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
11. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia.
Rosati R; La Starza R; Luciano L; Gorello P; Matteucci C; Pierini V; Romoli S; Crescenzi B; Rotoli B; Martelli MF; Pane F; Mecucci C
Leukemia; 2006 Sep; 20(9):1623-4. PubMed ID: 16838028
[No Abstract] [Full Text] [Related]
12. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
Shimomura Y; Maruoka H; Ishikawa T
Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
[TBL] [Abstract][Full Text] [Related]
13. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
Kjeldsen E
Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
[TBL] [Abstract][Full Text] [Related]
14. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
16. Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
Moshref Razavi H; Yu R
Am J Hematol; 2022 May; 97(5):668-669. PubMed ID: 35188683
[No Abstract] [Full Text] [Related]
17. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
18. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
20. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
